Website profile

Indian Pharma Post

Ajanta Pharma to hold 47th annual general meeting on July 16 Indian Pharma Post Get the latest News & Research on Pharma industry, Viewpoints, Events, Videos, statistics, indianpharmapost.com

  • 188articles · 30d
  • 9+ hour agolatest article
  • Aug 14, 2026earliest in window
  • 89%with images
  • 244avg words
articles per day
Categories
  • Medical 138
  • Health & Wellness 102
  • Economy, Business & Finance 80
  • Health 75
  • Business & Industrial 65
  • Finance & Business 33
  • Science & Technology 21
  • News 14
Bylines

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

@pharma_indian
indianpharmapost.com > policy > indian-pharmacopoeia-commission-organizes-national-conference-on-quality-and-safety-of-biosimilars-21816

Indian Pharmacopoeia Commission organizes national conference on quality and safety of biosimilars

12+ hour ago   (95+ words) The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, Government of India, organized a two-day National Conference on “Quality and Safety of Biosimilars: Strengthening India’s Biopharma SHAKTI Vision” on September 10–11, 2026, at the Centre…...

@pharma_indian
indianpharmapost.com > clinical-trials > novo-nordisk-trial-finds-semaglutide-cuts-obesity-in-children-aged-611-21773

Novo Nordisk trial finds semaglutide cuts obesity in children aged 6–11

4+ day, 3+ min ago   (63+ words) The findings are particularly significant because the trial population had a high burden of severe obesity Novo Nordisk trial finds semaglutide cuts obesity in children aged 6–11 MED-EL launches SONNET 3 cochlear implant audio processor in India Apollo Hospitals Navi Mumbai launches…...

@pharma_indian
indianpharmapost.com > news > aptar-pharma-and-aceso-therapeutics-partner-to-advance-novel-cystic-fibrosis-drug-candidate-21774

Aptar Pharma and Aceso Therapeutics partner to advance novel cystic fibrosis drug candidate

4+ day, 3+ hour ago   (88+ words) Indian Pharma Post Aptar Pharma and Aceso Therapeutics partner to advance novel cystic fibrosis drug candidate Nanopharm, Aptar Pharma’s specialist inhalation development services business, will lead formulation development and device assessment for ACT-101, supporting Aceso’s clinical development roadmap Chasing Consistency:…...

@pharma_indian
indianpharmapost.com > biopharma > biocon-inks-10-year-deal-to-supply-breast-cancer-therapy-to-brazil-21757

Biocon inks 10-year deal to supply breast cancer therapy to Brazil

4+ day, 21+ hour ago   (256+ words) Biocon Limited has signed a landmark partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil. This collaboration marks a significant step forward in scaling the production and commercialization of this HER2-positive breast cancer therapy under the country's Productive Development…...

@pharma_indian
indianpharmapost.com > news > alkem-launches-indias-first-patented-ginsenoside-exosome-hair-growth-serum-renocia-exo-21761

Alkem launches India’s first patented Ginsenoside Exosome hair growth Serum, Renocia Exo

4+ day, 21+ hour ago   (169+ words) Renocia Exo offers a new multitargeted approach to hair loss management by supporting the biology of the hair follicle-not just hair growth Alkem Laboratories has launched Renocia Exo, a next-generation hair regeneration therapy designed to scientifically support and vitalise hair…...

@pharma_indian
indianpharmapost.com > clinical-trials > novartis-pelacarsen-trial-fails-to-cut-cardiovascular-risk-21756

Novartis’ pelacarsen trial fails to cut cardiovascular risk

4+ day, 23+ hour ago   (54+ words) The pivotal cardiovascular outcomes trial did not meet its primary endpoint FDA moves to boost estradiol patch supply as demand surges Superluminal Medicines raises $60 million to push obesity drug into clinic Novartis’ pelacarsen trial fails to cut cardiovascular risk Indian…...

@pharma_indian
indianpharmapost.com > news > superluminal-medicines-raises-60-million-to-push-obesity-drug-into-clinic-21755

Superluminal Medicines raises $60 million to push obesity drug into clinic

5+ day, 4+ hour ago   (62+ words) Indian Pharma Post Superluminal Medicines raises $60 million to push obesity drug into clinic Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants Implementing a digital transformation in chemical operations to maximize profitability The complexity of compliance The…...

Google News
indianpharmapost.com > clinical-trials > summits-ivonescimab-delivers-overall-survival-win-against-pembrolizumab-in-phase-iii-lung-cancer-trial-21732

Summit’s ivonescimab delivers overall survival win against pembrolizumab in Phase III lung cancer trial

6+ day, 23+ hour ago   (68+ words) Indian Pharma Post Summit’s ivonescimab delivers overall survival win against pembrolizumab in Phase III lung cancer trial Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants Implementing a digital transformation in chemical operations to maximize profitability The…...

@pharma_indian
indianpharmapost.com > news > gan-lee-signs-up-to-726-million-menarini-deal-for-obesity-drug-in-europe-21733

Gan & Lee signs up to €726 million Menarini deal for obesity drug in Europe

1+ week, 5+ hour ago   (61+ words) The deal gives Gan & Lee a major European partner as the Chinese pharmaceutical company seeks to turn bofanglutide into a global metabolic-health product Priyanka Tewari appointed Head of Marketing at Glenmark Pharma Sonika Natalkar joins Lupin as Deputy General Manager…...

@pharma_indian
indianpharmapost.com > clinical-trials > novartis-remibrutinib-delivers-positive-phase-iii-results-in-relapsing-multiple-sclerosis-21671

Novartis’ Remibrutinib delivers positive Phase III results in relapsing multiple sclerosis

1+ week, 4+ day ago   (47+ words) The results point to potential benefits beyond relapse control Medtronic to invest $700 million in Hong Kong surgical robotics firm Scan.com raises $220 million to expand US medical imaging network India Glycols demerges biopharma business into separate entity Dr. Vineet Talwar…...